Screener / SEC EDGAR /CIK 0001048477 /10-K filed Feb 26, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Biomarin Pharmaceutical Inc BMRN

Compare with peers Embed
FY2025 at a glance

Sales up 12.9%, free cash flow up to $725.0M

XBRL, from each 10-K
RevenueStatements
$3.2B from $2.9B in FY2024
FY2016FY2025
Net incomeStatements
$348.9M from $426.9M in FY2024
FY2016FY2025
Free cash flowStatements
$725.0M from $487.4M in FY2024
FY2016FY2025
EPS (diluted)Statements
$1.80 from $2.21 in FY2024
FY2016FY2025
Operating marginStatements
12.7% from 17.0% in FY2024
FY2016FY2025
Total debtStatements
$597.2M

The latest figures

Price and key numbers

From EDGAR
All key numbers (45)
EPS (ttm)
-0.10
Sales (ttm)
3.7B
Net income (ttm)
-19.1M
Sales growth
+12.9%
EPS growth
-18.6%
Sales Q/Q
+32.0%
Free cash flow
557.9M
Gross margin
76.0%
Oper. margin
3.1%
Net margin
-0.5%
FCF margin
15.3%
R&D / sales
28.6%
Dividend
-
Debt/Eq
0.67
Curr. ratio
2.44
Cash
736.0M
Op. cash flow (ttm)
676.6M
EBITDA
489.0M
EBITDA margin
15.2%
Net debt
3.4B
Quick ratio
1.63
Interest cover
37.57
ROIC
2.8%
FCF after stock pay
543.5M
Debt / FCF (years)
5.76
Goodwill / assets
2.6%
Oper. margin low 5y
-4.5%
Tax rate
27.7%
Stock pay / sales
5.6%
Shares out.
193.7M
Shares Y/Y
+0.3%
Book / share
32.30
Cash / share
3.80
Sales / share
18.87
Asset turnover
0.32
Inventory turns
0.55
Days sales out.
103
Sales 3Y CAGR
+15.4%
Sales 5Y CAGR
+11.6%
EPS 3Y CAGR
+33.9%
EPS 5Y CAGR
-16.7%
Employees
3,221
Sales / employee
1.1M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.2B +12.5% a year Net income 348.9M
FY2016 revenue 1.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-005033 FY2016 net income -630.2M · NetIncomeLoss, 0001564590-19-005033 1.1B FY2016 FY2017 revenue 1.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-20-000009 FY2017 net income -117.0M · NetIncomeLoss, 0001048477-20-000009 1.3B FY2017 FY2018 revenue 1.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-21-000008 FY2018 net income -77.2M · NetIncomeLoss, 0001048477-21-000008 1.5B FY2018 FY2019 revenue 1.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-22-000012 FY2019 net income -23.8M · NetIncomeLoss, 0001048477-22-000012 1.7B FY2019 FY2020 revenue 1.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-23-000009 FY2020 net income 854.0M · NetIncomeLoss, 0001048477-23-000009 1.9B FY2020 FY2021 revenue 1.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-24-000016 FY2021 net income -64.1M · NetIncomeLoss, 0001048477-24-000016 1.8B FY2021 FY2022 revenue 2.1B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-25-000007 FY2022 net income 141.6M · NetIncomeLoss, 0001048477-25-000007 2.1B FY2022 FY2023 revenue 2.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-26-000004 FY2023 net income 167.6M · NetIncomeLoss, 0001048477-26-000004 2.4B FY2023 FY2024 revenue 2.9B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-26-000004 FY2024 net income 426.9M · NetIncomeLoss, 0001048477-26-000004 2.9B FY2024 FY2025 revenue 3.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001048477-26-000004 FY2025 net income 348.9M · NetIncomeLoss, 0001048477-26-000004 3.2B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share -16.7% a year FY2020 $4.50 to FY2025 $1.80, 5 years
Book value per share +7.5% a year FY2015 $15.00 to FY2025 $30.84, 10 years
Free cash flow per share +33.9% a year FY2021 $1.14 to FY2025 $3.67, 4 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $1.80$30.84$3.67
Dec 31, 2024 $2.21$28.76$2.48
Dec 31, 2023 $0.87$25.84$0.33
Dec 31, 2022 $0.75$24.36$0.29
Dec 31, 2021 -$0.35$23.33$1.14
Dec 31, 2020 $4.50$21.39-$0.15
Dec 31, 2019 -$0.13$17.44-$0.54
Dec 31, 2018 -$0.44$16.74-$0.70
Dec 31, 2017 -$0.67$16.10-$1.19
Dec 31, 2016 -$3.81$16.64-$2.26
Dec 31, 2015 -$1.07$15.00-$2.79

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $4.0B
  • − All liabilities $1.5B
  • = Net current asset value $2.4B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $6.1B
  • − Goodwill $196.2M
  • − Other intangible assets $213.8M
  • = Tangible book value $5.7B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

BMRN against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+12.9%63rd of 155 · median +10.5%
Net margin
-4.1%15.3%
-0.5%109th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-0.3%102nd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
15.3%51st of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.6752nd of 108 · median 0.69
BMRN and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
BMRN Biomarin Pharmaceutical Inc$3.7B +12.9%76.0%-0.5%-0.3%15.3%0.67
NBIX Neurocrine Biosciences Inc$3.7B +21.4%-19.0%18.1%28.1%-
XRAY DENTSPLY SIRONA Inc.$3.6B -3.0%50.5%-3.4%-8.9%2.9%1.62
VEEV Veeva Systems$3.5B +16.3%75.0%29.3%13.7%--
ACHC Acadia Healthcare Company, Inc.$3.4B +5.0%--33.1%-55.8%-0.7%1.16
WST West Pharmaceutical Services$3.4B +6.3%37.6%18.8%21.5%13.3%0.07
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $2.1B of sales to $141.6M of profit FY2022

Revenue to Gross profit: $1.6BRevenue to Cost of revenue: $503.0MGross profit to Operating profit: $161.0MGross profit to Operating expenses: $1.4BOperating profit to Net profit: $141.6MOperating profit to Tax & other: $19.4MOperating expenses to R&D: $649.6MOperating expenses to Sales, admin & other: $782.4M Revenue: $2.1B REVENUE $2.1B +14% Y/Y Gross profit: $1.6B · 76% margin GROSS PROFIT $1.6B 76% margin Cost of revenue: $503.0M · 24% of revenue COST OF REVENUE $503.0M 24% of revenue Operating profit: $161.0M · 8% margin OPERATING PROFIT $161.0M 8% margin Operating expenses: $1.4B · 68% of revenue OPERATING EXPENSES $1.4B 68% of revenue Net profit: $141.6M · 7% margin NET PROFIT $141.6M 7% margin Tax & other: $19.4M · 1% of revenue TAX & OTHER $19.4M 1% of revenue R&D: $649.6M · 31% of revenue R&D $649.6M 31% of revenue Sales, admin & other: $782.4M · 37% of revenue SALES, ADMIN & OTHER $782.4M 37% of revenue

From $2.4B of sales to $167.6M of profit FY2023

Revenue to Gross profit: $1.9BRevenue to Cost of revenue: $532.1MGross profit to Operating profit: $185.8MGross profit to Operating expenses: $1.7BOperating profit to Net profit: $167.6MOperating profit to Tax & other: $18.1MOperating expenses to R&D: $746.8MOperating expenses to Sales, admin & other: $954.6M Revenue: $2.4B REVENUE $2.4B +15% Y/Y Gross profit: $1.9B · 78% margin GROSS PROFIT $1.9B 78% margin Cost of revenue: $532.1M · 22% of revenue COST OF REVENUE $532.1M 22% of revenue Operating profit: $185.8M · 8% margin OPERATING PROFIT $185.8M 8% margin · +15% Y/Y Operating expenses: $1.7B · 70% of revenue OPERATING EXPENSES $1.7B 70% of revenue Net profit: $167.6M · 7% margin NET PROFIT $167.6M 7% margin · +18% Y/Y Tax & other: $18.1M · 1% of revenue TAX & OTHER $18.1M 1% of revenue R&D: $746.8M · 31% of revenue R&D $746.8M 31% of revenue Sales, admin & other: $954.6M · 39% of revenue SALES, ADMIN & OTHER $954.6M 39% of revenue

From $2.9B of sales to $426.9M of profit FY2024

Revenue to Gross profit: $2.3BRevenue to Cost of revenue: $580.2MGross profit to Operating profit: $484.2MGross profit to Operating expenses: $1.8BOperating profit to Net profit: $369.3MOperating profit to Tax: $114.9MOther income to Net profit: $57.5MOperating expenses to R&D: $747.2MOperating expenses to Sales, admin & other: $1.0B Revenue: $2.9B REVENUE $2.9B +18% Y/Y Gross profit: $2.3B · 80% margin GROSS PROFIT $2.3B 80% margin Cost of revenue: $580.2M · 20% of revenue COST OF REVENUE $580.2M 20% of revenue Operating profit: $484.2M · 17% margin OPERATING PROFIT $484.2M 17% margin · +161% Y/Y Other income: $57.5M · 2% of revenue OTHER INCOME $57.5M 2% of revenue Operating expenses: $1.8B · 63% of revenue OPERATING EXPENSES $1.8B 63% of revenue Net profit: $426.9M · 15% margin NET PROFIT $426.9M 15% margin · +155% Y/Y Tax: $114.9M · 4% of revenue TAX $114.9M 4% of revenue R&D: $747.2M · 26% of revenue R&D $747.2M 26% of revenue Sales, admin & other: $1.0B · 37% of revenue SALES, ADMIN & OTHER $1.0B 37% of revenue

From $3.2B of sales to $348.9M of profit FY2025

Revenue to Gross profit: $2.5BRevenue to Cost of revenue: $717.4MGross profit to Operating profit: $409.5MGross profit to Operating expenses: $2.1BOperating profit to Net profit: $275.9MOperating profit to Tax: $133.6MOther income to Net profit: $73.0MOperating expenses to R&D: $921.9MOperating expenses to SG&A: $1.2B Revenue: $3.2B REVENUE $3.2B +13% Y/Y Gross profit: $2.5B · 78% margin GROSS PROFIT $2.5B 78% margin Cost of revenue: $717.4M · 22% of revenue COST OF REVENUE $717.4M 22% of revenue Operating profit: $409.5M · 13% margin OPERATING PROFIT $409.5M 13% margin · −15% Y/Y Other income: $73.0M · 2% of revenue OTHER INCOME $73.0M 2% of revenue Operating expenses: $2.1B · 65% of revenue OPERATING EXPENSES $2.1B 65% of revenue Net profit: $348.9M · 11% margin NET PROFIT $348.9M 11% margin · −18% Y/Y Tax: $133.6M · 4% of revenue TAX $133.6M 4% of revenue R&D: $921.9M · 29% of revenue R&D $921.9M 29% of revenue SG&A: $1.2B · 36% of revenue SG&A $1.2B 36% of revenue

Where each $100 of sales went

FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Sales, admin & other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 5.7% FY2020: 20.8% net income ÷ equity
Net margin 10.8% FY2020: 45.9% profit per $ of sales: 348.9M ÷ 3.2B
Asset turnover 0.42× FY2020: 0.32× sales per $ of assets: 3.2B ÷ 7.6B
Leverage 1.25× FY2020: 1.43× assets per $ of equity: 7.6B ÷ 6.1B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -0.5% vs 6.8%
  • Return on equity below 15%
    -0.3%
  • A profit in 5 of 10 years
Net margin, FY2016 to FY2025: -56.4% to 10.8%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 37.6× interest expense
  • Debt smaller than equity
    Debt / equity 0.67 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 2.44
  • Net debt over 3 years of free cash flow
    $3.2B net debt, 5.7 years

Cash and shareholders

  • Free cash flow positive in 5 of 10 years
    $725.0M last year
  • Share count up over 5 years
    +3.0%
  • Cash from operations above net income
    $828.0M vs $348.9M
Free cash flow, FY2016 to FY2025: -376.2M to 725.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$- of principal due

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

BMRN's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.2B
FY2016: 1.1BFY2017: 1.3BFY2018: 1.5BFY2019: 1.7BFY2020: 1.9BFY2021: 1.8BFY2022: 2.1BFY2023: 2.4BFY2024: 2.9BFY2025: 3.2B FY2017FY2019FY2021FY2023FY2025
Net income348.9M
FY2016: -630.2MFY2017: -117.0MFY2018: -77.2MFY2019: -23.8MFY2020: 854.0MFY2021: -64.1MFY2022: 141.6MFY2023: 167.6MFY2024: 426.9MFY2025: 348.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow725.0M
FY2016: -376.2MFY2017: -208.0MFY2018: -124.4MFY2019: -96.8MFY2020: -28.9MFY2021: 209.0MFY2022: 54.9MFY2023: 62.6MFY2024: 487.4MFY2025: 725.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay543.5M
FY2016: -510.9MFY2017: -348.2MFY2018: -273.2MFY2019: -256.6MFY2020: -218.7MFY2021: 11.7MFY2022: -141.4MFY2023: -144.5MFY2024: 285.8MFY2025: 543.5M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)1.80
FY2016: -3.81FY2017: -0.67FY2018: -0.44FY2019: -0.13FY2020: 4.50FY2021: -0.35FY2022: 0.75FY2023: 0.87FY2024: 2.21FY2025: 1.80 FY2017FY2019FY2021FY2023FY2025
Diluted shares197.4M
FY2016: 166.2MFY2017: 174.4MFY2018: 177.3MFY2019: 179.0MFY2020: 191.7MFY2021: 182.9MFY2022: 189.0MFY2023: 191.6MFY2024: 196.7MFY2025: 197.4M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
VOXZOGO 926.9M28.8% +26.1%
VIMIZIM 792.1M24.6% +7.1%
NAGLAZYME 485.4M15.1% +1.2%
PALYNZIQ 433.3M13.5% +22.0%
ALDURAZYME 208.5M6.5% +13.4%
BRINEURA 186.4M5.8% +10.2%
KUVAN 99.5M3.1% -17.7%
Royalty and other revenues 53.5M1.7% +20.3%
ROCTAVIAN 35.6M1.1% +36.7%

10-K 0001048477-26-000004, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.1B1.3B1.5B1.7B1.9B1.8B2.1B2.4B2.9B3.2B
Cost of revenue209.6M241.8M315.3M359.5M524.3M470.5M503.0M532.1M580.2M717.4M
R&D661.9M610.8M696.3M715.0M628.1M628.8M649.6M746.8M747.2M921.9M
SG&A476.6M554.3M604.4M680.9M737.7M759.4M823.2M892.4M1.0B1.2B
Operating income-803.4M-14.7M-123.5M-100.5M-43.4M-82.3M161.0M185.8M484.2M409.5M
Interest expense39.5M42.7M43.7M23.5M29.3M15.3M16.0M17.3M12.7M10.9M
Pretax income-831.0M-35.9M-142.7M-94.8M-49.0M-75.3M149.6M188.6M541.8M482.5M
Income tax-200.8M81.2M-65.5M-71.0M-903.0M-11.3M8.0M20.9M114.9M133.6M
Net income-630.2M-117.0M-77.2M-23.8M854.0M-64.1M141.6M167.6M426.9M348.9M
EPS (diluted)-3.81-0.67-0.44-0.134.50-0.350.750.872.211.80
Diluted shares166.2M174.4M177.3M179.0M191.7M182.9M189.0M191.6M196.7M197.4M
Depreciation & amortization96.9M87.9M95.7M105.3M105.2M108.0M102.0M104.4M96.4M79.6M
EBITDA-706.5M73.2M-27.9M4.8M61.7M25.7M262.9M290.2M580.6M489.0M
Operating margin-71.9%-1.1%-8.3%-5.9%-2.3%-4.5%7.7%7.7%17.0%12.7%
Net margin-56.4%-8.9%-5.2%-1.4%45.9%-3.5%6.8%6.9%15.0%10.8%
Revenue growth+25.5%+17.6%+13.5%+14.3%+9.2%-0.8%+13.5%+15.4%+18.0%+12.9%
EPS growth-----to a loss-+16.0%+154%-18.6%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-227.8M-8.8M20.2M48.3M85.4M304.5M175.9M159.3M572.8M828.0M
Capital spending148.4M199.2M144.6M145.0M114.3M95.6M121.0M96.7M85.4M103.0M
Free cash flow-376.2M-208.0M-124.4M-96.8M-28.9M209.0M54.9M62.6M487.4M725.0M
Stock-based pay (added back)134.6M140.3M148.8M159.9M189.7M197.3M196.3M207.1M201.6M181.4M
Free cash flow after stock pay-510.9M-348.2M-273.2M-256.6M-218.7M11.7M-141.4M-144.5M285.8M543.5M
Buybacks--0050.0M00---
Acquisitions2.8M00-------
Investing cash flow-484.0M-305.5M264.4M-31.0M-53.6M-366.3M-20.0M-111.2M136.5M-414.2M
Financing cash flow727.1M507.1M-388.0M-74.7M181.1M-48K-18.6M-18.7M-526.4M-42.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)134.6M140.3M148.8M159.9M189.7M197.3M196.3M207.1M201.6M181.4M
Stock-based pay / revenue12.1%10.7%10.0%9.4%10.2%10.7%9.4%8.6%7.1%5.6%
Operating lease cash paid---8.2M10.5M10.7M10.8M10.0M13.4M9.3M
Finance lease principal paid---5.1M6.9M3.0M2.6M2.3M216K889K
Right-of-use assets---49.0M46.0M38.2M34.9M42.7M28.7M35.2M
Operating lease liabilities---51.5M49.4M40.1M34.4M46.7M37.7M45.1M
Finance lease liabilities---10.0M6.9M4.2M2.5M216K1.1M552K

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.